Sino-U.S. To Jointly Set Up Medical Device R&D Base In Shenzhen
This article was originally published in PharmAsia News
Executive Summary
Shenzhen Institute of Advanced Technology, a branch of the Chinese Academy of Sciences, and American medical device company STI Medical Systems will jointly set up a high-level medical device R&D base in Shenzhen. The collaboration will focus on five areas: (1) STI will invest in SIAT and set up the R&D facility; (2) STI and SIAT will jointly apply for research grants from the U.S. National Science Foundation, National Institutes of Health and the U.S. FDA; (3) SIAT may send its students for internships in the U.S; (4) both organizations will incorporate their funding, technology, talent and facilities as well as research management experience; and (5) both will establish an integrated industry application laboratory and possibly a joint venture firm when future conditions are ripe. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.